A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Atara Biotherapeutics
Atara Biotherapeutics
The First Affiliated Hospital with Nanjing Medical University
Astellas Pharma Inc
CRISPR Therapeutics
Roswell Park Cancer Institute
Adicet Therapeutics
CARGO Therapeutics
Thomas Jefferson University